Carmen Espejo Ruiz I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies. Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Carmen Espejo Ruiz LinkedIn Twitter Orcid Email Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.
I obtained my degree in Biology from the University of Barcelona in 1998. I did my doctoral thesis at the Clinical Neuroimmunology Unit of the Hospital Universitari Vall d'Hebron, in which I studied the role of metallothioneins in the pathogenesis of multiple sclerosis, obtaining my PhD in Biology from the University of Barcelona in 2005. In 2008, I got a Miguel Servet contract that allowed me to establish myself as principal investigator of the Clinical Neuroimmunology group – Multiple Sclerosis Centre of Catalonia. Currently, I am a senior researcher at the Vall d'Hebron Research Institute and develop my scientific activity in the Clinical Neuroimmunology group - Center d'Esclerosi Múltiple de Catalunya. My main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim of developing new therapeutic strategies. I am currently focused on the role of immunosenescence in the pathogenesis of multiple sclerosis and the therapeutic potential of different senolytic drugs. I am also studying how the modification of the gut microbiota, through the administration of probiotics, could constitute a therapeutic tool in multiple sclerosis. Finally, I am carrying out a project that aims to induce immune tolerance, through the use of nanomedicine, with the aim of slowing down the autoimmune response in multiple sclerosis. I have more than 25 years of experience in animal models of multiple sclerosis and in the study of the immune response. At the Vall d'Hebron Research Institute, I am a member (since 2003) and the president (since 2006) of the Animal Experimentation Ethics Committee. I am also part of the Biosafety Committee (since 2015) and the Research Integrity Committee (since 2020). I have participated, as main or collaborating author, in 70 publications indexed in peer review journals. I have supervised eight doctoral theses and eight master's final projects. In addition, I participated as a teacher in various training activities, including the Master of Advanced Immunology at the Autonomous University of Barcelona and the University of Barcelona.
Projects SGR-Cat 2021: Neuroimmunologia Clínica IP: SGR-Cat 2021: Neuroimmunologia Clínica Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, SGR-Cat 2021: Neuroimmunologia Clínica, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, SGR-Cat 2021: Neuroimmunologia Clínica, M Jesus Arevalo Navines, SGR-Cat 2021: Neuroimmunologia Clínica, Augusto Cesar Sao Aviles, SGR-Cat 2021: Neuroimmunologia Clínica, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, SGR-Cat 2021: Neuroimmunologia Clínica, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 00782 Duration: 01/01/2022 - 30/06/2025 Valorización de una terapia antígeno-específica para el tratamiento disruptivo de la diabetes tipo 1; esclerosis múltiple, miastenia gravis, enfermedad celíaca y artritis reumatoide. IP: Carmen Espejo Ruiz Collaborators: Sara Marsal Barril, Herena Eixarch Ahufinger, Helena Borrell Paños, Maria America Lopez Lasanta Funding agency: Ministerio Ciencia, Innovación y Universidades Funding: 217313.9 Reference: CPP2021-008475 Duration: 10/02/2022 - 31/12/2025 Rejuvenation of the immune system as a therapeutic approach for progressive multiple sclerosis. IP: Carmen Espejo Ruiz Collaborators: Rosalia Horno Ocaña, Herena Eixarch Ahufinger, Breogan Rodriguez Acevedo, Mireia Castillo Juarez Funding agency: Instituto de Salud Carlos III Funding: 159720 Reference: PI21/01682 Duration: 01/01/2022 - 30/06/2026 ADQUISICIÓN DE UN MICROSCOPIO CONFOCAL ESPECTRAL DE RASTREO DE ALTA RESOLUCIÓN DESTINADO A LA PLATAFORMA DE MICROSCOPÍA DE LA UNIDAD DE ALTA TECNOLOGÍA (UAT) IP: Inmaculada Fuentes Camps Collaborators: Miquel Vila Bover, Anna Meseguer Navarro, José García Arumí, Miguel Segura Ginard, Victor Franco Puntes, Anna Santamaria Margalef, Carmen Espejo Ruiz, María José Buzón Gómez, Javier Inserte Igual, Anna Rosell Novel, Trond Aasen Funding agency: Ministerio Ciencia, Innovación y Universidades Funding: 502000 Reference: EQC2019-006247-P Duration: 01/01/2019 - 31/12/2020 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 … Next page › Last page »
